ITP and B-cell Lymphoma Feature in Latest BSH Guidance ITP and B-cell Lymphoma Feature in Latest BSH Guidance
Recommendations on tackling osteoporosis in immune thrombocytopenia and mediastinal B-cell lymphoma management are the latest guidance by the British Society for Haematology in a prolific year.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 5, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Flash-Mob Audit Shows Ig Overused in Immune Thrombocytopenia Flash-Mob Audit Shows Ig Overused in Immune Thrombocytopenia
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Ig Overused in Immune Thrombocytopenia, Flash Mob Audit Shows Ig Overused in Immune Thrombocytopenia, Flash Mob Audit Shows
A novel form of audit that pooled data from a large number of centres over a short period of time has revealed that many UK immune thrombocytopenia patients are not receiving recommended therapy.Medscape News UK (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 2, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes
Cytopenias are an important clinical problem associated with inflammatory disease and infection. We show that specialized phagocytes that internalize red blood cells develop in Toll-like receptor 7 (TLR7)–driven inflammation. TLR7 signaling caused the development of inflammatory hemophagocytes (iHPCs), which resemble splenic red pulp macrophages but are a distinct population derived from Ly6Chi monocytes. iHPCs were responsible for anemia and thrombocytopenia in TLR7-overexpressing mice, which have a macrophage activation syndrome (MAS)–like disease. Interferon regulatory factor 5 (IRF5), associated with MAS, p...
Source: ScienceNOW - January 10, 2019 Category: Science Authors: Akilesh, H. M., Buechler, M. B., Duggan, J. M., Hahn, W. O., Matta, B., Sun, X., Gessay, G., Whalen, E., Mason, M., Presnell, S. R., Elkon, K. B., Lacy-Hulbert, A., Barnes, B. J., Pepper, M., Hamerman, J. A. Tags: Immunology, Online Only r-articles Source Type: news

Amgen Submits Supplemental Biologics License Application For Nplate ® (romiplostim)
Application Seeks to Include Adult Patients who Have had Immune Thrombocytopenia for 12 Months or Less THOUSAND OAKS, Calif., Dec. 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate® (romiplostim) to include the treatment of adult patients with immune thrombocytopenia (ITP) who have had ITP for 12 months or less and an insufficient response to corticosteroids, immunoglobulins or splenectomy. "Patients living with ITP need more flexibility in their treatment options, and we...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Choosing Wisely Champions Cut Blood RBC Transfusions, HIT testing Choosing Wisely Champions Cut Blood RBC Transfusions, HIT testing
Two researchers hailed as'Choosing Wisely Champions'describe how they reduced blood transfusions and inappropriate testing for heparin-induced thrombocytopenia (HIT).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Nplate ® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
Application Granted Priority Review Designation Approval Based on Results That Demonstrated Nplate Successfully Increased and Sustained Platelet Counts in Children Affected by Rare Blood Disorder THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immunoglob...
Source: Amgen News Release - December 14, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

EMA Panel Backs Lusutrombopag for Adults With Liver Disease EMA Panel Backs Lusutrombopag for Adults With Liver Disease
The thrombopoietin receptor agonist is for severe thrombocytopenia in adults with chronic liver disease who are scheduled to undergo an invasive procedure.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

FDA Approves Nplate (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate (romiplostim) for the treatment of pediatric... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2018 Category: Drugs & Pharmacology Source Type: news

CNIO finds the origin of a type of thrombocytopenia caused by an oncogene
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) This work has allowed to understand, through the study of MASTL protein, the molecular origin of inherited thrombocytopenia in some patients and to successfully explore therapeutic options on a mouse model.MASTL controls the cytoskeleton, the structure that gives cells their shape and governs their mobility and capacity for grouping.Abnormalities in the cytoskeleton of tumor cells facilitate their spreading throughout the body of cancer patients, which is why studying MASTL might have important implications on how to block metastasis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 31, 2018 Category: Cancer & Oncology Source Type: news

Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
First SYK inhibitor for the treatment of adult chronic ITP SOUTH SAN FRANCISCO, Calif., Oct. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the European Medicines Agency (EMA) has v... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, fostamatinib, TAVALISSE, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 11, 2018 Category: Pharmaceuticals Source Type: news

Fostamatinib Seems Effective for Immune Thrombocytopenia
Overall response of platelet count ≥ 50,000/ μ L seen in 43 percent of patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 5, 2018 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Journal, Source Type: news

Fostamatinib Seems Effective for Immune Thrombocytopenia
WEDNESDAY, Sept. 5, 2018 -- Fostamatinib produces clinically meaningful responses in adults with immune thrombocytopenia (ITP), according a study published in the July issue of the American Journal of Hematology. James Bussel, M.D., from Weill... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 5, 2018 Category: Pharmaceuticals Source Type: news

Sanofi nabs EU approval for first treatment of rare blood-clotting disorder
Cablivi is the first therapeutic approved for the treatment of aTTP, an autoimmune-based blood clotting disorder characterized by extensive clot formation in small blood vessels throughout the body, leading to severe thrombocytopenia (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - September 4, 2018 Category: Pharmaceuticals Source Type: news

Invasive longhorned tick found for the first time in NYC
The city health department announced Wednesday that the longhorned tick has been spotted in the borough of Staten Island. It is known to transmit severe fever with thrombocytopenia in Asia. (Source: the Mail online | Health)
Source: the Mail online | Health - August 8, 2018 Category: Consumer Health News Source Type: news

FDA Approves Mulpleta (lusutrombopag) for Thrombocytopenia in Adults with Chronic Liver Disease
On July 31, 2018, the Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. Approval was based on two... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Lusutrombopag for Thrombocytopenia in Liver Disease FDA OKs Lusutrombopag for Thrombocytopenia in Liver Disease
The thrombopoietin receptor agonist is for adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 1, 2018 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

FDA approves blood disorder drug made by Japan's Shionogi
The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi& Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease. (Source: Reuters: Health)
Source: Reuters: Health - July 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Spurious Thrombocytopenia in Automated Platelet Count Spurious Thrombocytopenia in Automated Platelet Count
This article underscores the need for healthcare professionals to be aware of the possibility of spurious data from automated PLT counts. What factors might contribute to these false results?Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Pre-op Avatrombopag Curbs Platelet Need in Patients With Liver Disease Pre-op Avatrombopag Curbs Platelet Need in Patients With Liver Disease
Pre-procedural avatrombopag (Doptelet, Dova) may reduce the need for platelet transfusions or rescue procedures for bleeding in patients with chronic liver disease (CLD) and thrombocytopenia, according to findings from two phase 3 trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Approves Doptelet (avatrombopag) for Thrombocytopenia Patients with Chronic Liver Disease who are Undergoing a Medical Procedure
May 21, 2018 -- The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 22, 2018 Category: Drugs & Pharmacology Source Type: news

FDA Approves Doptelet (avatrombopag) for Chronic Liver Disease Patients with Thrombocytopenia who are Undergoing a Medical Procedure
May 21, 2018 -- The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 22, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Platelet Booster for Liver Disease Patients FDA OKs Platelet Booster for Liver Disease Patients
Avatrombopag increases platelet counts and may decrease or eliminate the need for transfusions in patients with liver disease and thrombocytopenia who are to undergo a planned medical or dental procedure.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 21, 2018 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

Toxic thrombocytopenia during Nerium oleander poisoning - Bataille C, Capaldo L, Courtois A, Seguy B, Lotiron C, Labadie M.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - May 21, 2018 Category: International Medicine & Public Health Tags: Home and Consumer Product Safety Source Type: news

FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure
FDA approves Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical procedure. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 21, 2018 Category: American Health Source Type: news

FDA Approves Tavalisse (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia
SOUTH SAN FRANCISCO, Calif., April 17, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved Tavalisse (fostamatinib disodium hexahydrate) for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2018 Category: Drugs & Pharmacology Source Type: news

Severe fever with thrombocytopenia syndrome complicated by invasive aspergillosis
Tue, 03/27/2018 - 14:06News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - March 27, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Akers Bio signs 3-year distribution deal with Diagnostica Stago
Akers Biosciences Inc. has entered into a three-year national distribution agreement for its flagship product with Diagnostica Stago Inc. Under the three-year deal, Stago will distribute South Jersey-based Akers PIFA PLUSS PF4 Rapid Assay, a single-use test for Heparin-induced thrombocytopenia to its customer base of hospital laboratories across the United States. Heparin-induced thrombocytopenia (HIT) is a clinical syndrome that r everses heparin's intended blood-thinning therapeutic effect and… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 26, 2018 Category: Health Management Authors: John George Source Type: news

Akers Bio signs 3-year distribution deal with Diagnostica Stago
Akers Biosciences Inc. has entered into a three-year national distribution agreement for its flagship product with Diagnostica Stago Inc. Under the three-year deal, Stago will distribute South Jersey-based Akers PIFA PLUSS PF4 Rapid Assay, a single-use test for Heparin-induced thrombocytopenia to its customer base of hospital laboratories across the United States. Heparin-induced thrombocytopenia (HIT) is a clinical syndrome that r everses heparin's intended blood-thinning therapeutic effect and… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 26, 2018 Category: Biotechnology Authors: John George Source Type: news

Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia
A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies. (Source: CancerNetwork)
Source: CancerNetwork - March 21, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Myeloproliferative Neoplasms News Source Type: news

Pacritinib Can Fill Unmet Need in Myelofibrosis Pacritinib Can Fill Unmet Need in Myelofibrosis
Investigational agent pacritinib holds promise as a treatment option for patients with myelofibrosis and baseline thrombocytopenia.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Antiplatelet Therapy in ACS Patients With Thrombocytopenia Antiplatelet Therapy in ACS Patients With Thrombocytopenia
ACS patients with thrombocytopenia are at higher risk of both bleeding and ischemic events, making treatment particularly challenging. How should management be approached?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes Romiplostim Not Tied to Leukemic Progression in Myelodysplastic Syndromes
Contrary to initial reports, romiplostim treatment of thrombocytopenia does not appear to increase the risk of progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 2, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Your NEJM Group Today: Headache, Anemia, and Thrombocytopenia / Top Gastroenterology Stories / California Faculty Positions
Here's what we've chosen for you today from NEJM Group: NEJM Clinical Practice Center: Case Record: A 32-year-old woman was admitted to the... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 4, 2018 Category: Primary Care Source Type: news

Rigel Announces Departure of Chief Financial Officer
Launches Search for Chief Financial Officer with Commercial-Stage Expertise SOUTH SAN FRANCISCO, Calif., Dec. 15, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the resignation of Ryan Mayna... Biopharmaceuticals, Personnel Rigel Pharmaceuticals, fostamatinib, tyrosine kinase, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 15, 2017 Category: Pharmaceuticals Source Type: news

Novartis says ‍revolade shows long-term disease control for chronic/persistent immune thrombocytopenia​
ZURICH (Reuters) - Novartis said on Wednesday a long term study of ‍its Revolade drug showed good results in treating chronic and persistent immune thrombocytopenia (ITP) - a condition where patients' blood does not clot normally. (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Brian L. Kotzin, M.D. has been appointed to Rigel's board of directors. A well-respected former profess... Biopharmaceuticals, Personnel Rigel Pharmaceuticals, Tavalisse, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 25, 2017 Category: Pharmaceuticals Source Type: news

FDA Accepts Rigel's New Drug Application for TAVALISSE(TM) (fostamatinib disodium) for the Treatment of Chronic ITP
SOUTH SAN FRANCISCO, Calif., June 19, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of TAVALISS... Biopharmaceuticals, FDA Rigel Pharmaceuticals, TAVALISSE, fostamatinib, thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 19, 2017 Category: Pharmaceuticals Source Type: news

A Newborn With Cutaneous Lesions and Hematochezia A Newborn With Cutaneous Lesions and Hematochezia
Can you identify the underlying cause of this newborn's dermal lesion, thrombocytopenia, and rectal bleeding?Medscape Pediatrics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2017 Category: Consumer Health News Tags: Pediatrics Clinical Case Source Type: news

What Causes Anemia?
Discussion One of the most common problems in pediatrics is anemia. It is defined as “a lower than normal value for the related measurements of hemoglobin, hematocrit, and number of red blood cells”, usually 2 standard deviations below the normal for age. Normal hematological values change with age. For a discussion of which values are used click here. The most common type of anemia in childhood is iron deficiency which is commonly caused by inadequate stores (e.g. premature infant), inadequate intake (e.g. poor nutrition) or blood loss (e.g. menses). Anemia screening is recommended at age 9-12 months, and for...
Source: PediatricEducation.org - May 15, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Rigel Announces Tavalisse(TM) as Proprietary Name for Fostamatinib in the United States
SOUTH SAN FRANCISCO, Calif., April 27, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Tavalisse™... Biopharmaceuticals, Oncology Rigel Pharmaceuticals, Tavalisse, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 27, 2017 Category: Pharmaceuticals Source Type: news

Rigel Pharmaceuticals submits NDA to FDA for Fostamatinib to treat chronic ITP
Rigel Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for an oral investigational drug candidate, Fostamatinib, for the treatment of chronic and persistent immune thrombocytopenia (ITP). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 19, 2017 Category: Pharmaceuticals Source Type: news

Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
SOUTH SAN FRANCISCO, Calif., April 17, 2017 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fosta... Biopharmaceuticals Rigel Pharmaceuticals, fostamatinib, immune thrombocytopenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 17, 2017 Category: Pharmaceuticals Source Type: news

Presentation of Severe Fever With Thrombocytopenia Syndrome Presentation of Severe Fever With Thrombocytopenia Syndrome
This case details an unusual presentation of encephalopathy in a patient with severe fever with thrombocytopenia syndrome, an emerging infectious disease that has recently been identified in Asia.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Eltrombopag Improved Platelet Counts in Thrombocytopenic MDS Patients
The use of the thrombopoietin receptor agonist eltrombopag was clinically effective at raising platelet counts in patients with lower-risk myelodysplastic syndromes with severe thrombocytopenia. (Source: CancerNetwork)
Source: CancerNetwork - February 10, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news

Ocular Complications of Congenital Infections
This article summarizes the ocular complications of the 5 infections typically represented by the acronym TORCHES (toxoplasmosis, rubella, cytomegalovirus, herpes simplex, and syphilis), as well as others, including newer pathogens such as the human immunodeficiency, West Nile, and Zika viruses. (Source: NeoReviews recent issues)
Source: NeoReviews recent issues - February 1, 2017 Category: Pediatrics Authors: Khazaeni, L. M. Tags: Pediatric Drug Labeling Update Articles Source Type: news

[Report] IgG antibodies to dengue enhanced for Fc γRIIIA binding determine disease severity
Dengue virus (DENV) infection in the presence of reactive, non-neutralizing immunoglobulin G (IgG) (RNNIg) is the greatest risk factor for dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Progression to DHF/DSS is attributed to antibody-dependent enhancement (ADE); however, because only a fraction of infections occurring in the presence of RNNIg advance to DHF/DSS, the presence of RNNIg alone cannot account for disease severity. We discovered that DHF/DSS patients respond to infection by producing IgGs with enhanced affinity for the activating Fc receptor FcγRIIIA due to afucosylated Fc glycans and IgG1...
Source: ScienceNOW - January 26, 2017 Category: Science Authors: Taia T. Wang Source Type: news

Severe Thrombocytopenia in a Child With Typhoid Fever Severe Thrombocytopenia in a Child With Typhoid Fever
How should thrombocytopenia in typhoid fever be managed? The successful outcome of this occurrence in a young traveler provides some guidance.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 6, 2017 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia, Multiple Myeloma And Immune Thrombocytopenia At ASH 2016
Sub-Analysis From Phase 3 TOWER Study Compares Health-Related Quality of Life of BLINCYTO® (Blinatumomab) to Standard of Care Chemotherapy Analysis of Phase 3 Data Evaluates Cost-Effectiveness of KYPROLIS® (Carfilzomib) in Combination With Dexamethasone for Relapsed Multiple Myeloma Patients Long-Term Data Provide Insights on Safety and Efficacy of Nplate® (Romiplostim) in Children With Immune Thrombocytopenia THOUSAND OAKS, Calif., Nov. 30, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data will be presented at the 58th Annual Meeting and Exposition of the American Society of Hemat...
Source: Amgen News Release - November 30, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news